Literature DB >> 25283719

Autoantibodies to neurofascin-186 and gliomedin in multifocal motor neuropathy.

Francesca Notturno1, Tiziana Di Febo2, Nobuhiro Yuki3, Blanca M Fernandez Rodriguez4, Davide Corti4, Eduardo Nobile-Orazio5, Marinella Carpo6, Angelo De Lauretis7, Antonino Uncini8.   

Abstract

We tested autoantibodies to neurofascin-186 (NF186) and gliomedin in sera from patients with multifocal motor neuropathy (MMN, n=53) and chronic inflammatory demyelinating polyneuropathy (CIDP, n=95) by ELISA. IgG antibodies to NF186 or gliomedin were found in 62% of MMN and 1% of CIDP sera, and IgM antibodies to the same antigens in 12% of MMN and 1% of CIDP sera. These autoantibodies activated complement. Ten percent of the MMN sera without IgM anti-GM1 reactivity had anti-NF186 antibodies. Because NF186 and gliomedin play a crucial role for salutatory conduction, the autoantibodies may contribute to produce motor nerve conduction block and muscle weakness in MMN.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic inflammatory demyelinating neuropathy; Gliomedin; Multifocal motor neuropathy; Neurofascin

Mesh:

Substances:

Year:  2014        PMID: 25283719     DOI: 10.1016/j.jneuroim.2014.09.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases.

Authors:  Chong Xie; Ze Wang; Nan Zhao; Desheng Zhu; Xiajun Zhou; Jie Ding; Yifan Wu; Haojun Yu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-15       Impact factor: 3.307

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

3.  The olfactomedin domain from gliomedin is a β-propeller with unique structural properties.

Authors:  Huijong Han; Petri Kursula
Journal:  J Biol Chem       Date:  2014-12-17       Impact factor: 5.157

4.  Anti-neurofascin 186 antibody in amyotrophic lateral sclerosis: a case report.

Authors:  Shen Liu; Yi-Ming Zhang; Hong-Dong Zhao; Ting-Ting Liu; Jian-Quan Shi
Journal:  Acta Neurol Belg       Date:  2022-05-27       Impact factor: 2.396

Review 5.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

6.  Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders.

Authors:  Delmont Emilien; Willison Hugh
Journal:  J Neuromuscul Dis       Date:  2015-06-04

7.  Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP.

Authors:  M Staudt; J M Diederich; C Meisel; A Meisel; J Klehmet
Journal:  BMC Neurol       Date:  2017-04-26       Impact factor: 2.474

8.  Contactin-1 and Neurofascin-155/-186 Are Not Targets of Auto-Antibodies in Multifocal Motor Neuropathy.

Authors:  Kathrin Doppler; Luise Appeltshauser; Heidrun H Krämer; Judy King Man Ng; Edgar Meinl; Carmen Villmann; Peter Brophy; Sulayman D Dib-Hajj; Stephen G Waxman; Andreas Weishaupt; Claudia Sommer
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

Review 9.  Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.

Authors:  Atay Vural; Kathrin Doppler; Edgar Meinl
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

10.  Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis.

Authors:  Wenyu Hu; Yanguo Xin; Zhiyi He; Yinan Zhao
Journal:  Brain Behav       Date:  2018-09-21       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.